This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Fred Levine, MD, PhD; Theodore Friedmann, MD

Am J Dis Child. 1993;147(11):1167-1174.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Genetics is playing an increasingly important role in medicine. It has become clear that genetic factors are involved in virtually every disease that afflicts humanity. Although conventional pharmacologic therapy is effective for many diseases, the underlying genetic predispositions that lead to the diseases are not influenced by these therapies. In particular, with few exceptions, therapy is woefully inadequate for diseases that follow a simple mendelian pattern of inheritance and thus are caused primarily by a single genetic defect.

The ultimate goal of treatment of genetic disease is repair of the genetic defect, ie, gene therapy.^1,2 In the past few years, there has been an explosion of interest in this new form of medical treatment. As gene therapy increasingly moves from research laboratories to clinical trials, it will inevitably become standard therapy for many diseases commonly seen by general pediatricians, such as cystic fibrosis (CF), hemophilia, and sickle cell anemia. Thus, . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Pediatrics, Center for Molecular Genetics, University of California, San Diego, La Jolla.

Footnotes
Accepted for publication June 21, 1993.

Reprint requests to Department of Pediatrics, Center for Molecular Genetics, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093-0634 (Dr Levine).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?